CCX’s Post

Just for some practical examples, at the #EPAconf in Amsterdam a few days ago, one of my advisors Mel Walker led an excellent panel with Robert Kettell, Christopher Kipps, Elena Tricca, and Prof. Lotte Steuten, PhD on how industry and payers are working together in the UK to address structural access issues such as combination pricing, unwarranted uptake variation, and the data fueling innovative payment models. We should continue to collaborate across structural issues and share the lessons learned.

Nathan Sigworth’s analysis of the shift from positional to structural leverage in European Market Access highlights a critical evolution in healthcare negotiations. This shift demands more than just innovative negotiation tactics; it requires pharmaceutical companies to integrate market access as a fundamental organizational capability, leveraging expertise, stakeholder networks, and innovative technologies. Success in this complex landscape hinges not only on collaborative problem-solving but also on embedding market access strategically across all organizational levels. Embracing this comprehensive approach is essential for navigating the intricacies of global healthcare access and ensuring the delivery of life-changing therapies to those in need.